All right. All right. Well, good afternoon, everyone. Thank you for joining us. I hope everyone had a great lunch here at the UBS Global Biopharma Conference. I'm Michael Yee, Global Head of Biotech Research here at UBS. Really pleased to have on stage with us Beam Therapeutics, Chief Executive Officer John Evans. Thank you so much for being here with us.
Great to be here. Thank you.
Fantastic. Beam has had an exciting year. You've been reporting a lot of data across not only your lead program, sickle cell, which just had an update, but also across the AAT program, and also some early data across GSD1a too. Let's talk about some of that. Maybe if I could just offer you an opportunity to make some opening comments. Where are you with these three programs, and what are the next key milestones as you think about some of these key programs?
Great. Yeah. Thank you for having me again, and we are having a very exciting year. I think this is the year when the full potential of this platform that we've been building is now really visible.
Yeah.
Particularly the fact that it is a platform technology. This is base editing, where we are going to fix single letters in genes to correct for mutations, and it is delivery that is very well validated at this point, whether it be an ex vivo transplant or a lipid nanoparticle. Once those begin to work, they keep working, and we have every reason to believe that the next version of that technology, the next time we put it into patients, different disease, we should get the same positive result, and we are starting to see that now. So across those programs, with sickle cell disease, as you noted, we just had the top line data, just top line release, but it is positive, so that is great. That keeps us on track for a BLA filing, as early as December. So we are hard at work right now on that.
We can talk a lot more about that, but very exciting, highly differentiated program for patients with sickle cell disease.
You are hosting something at ASH, I think, too.
Yes. Yep. That is going to be a nice event. Yep, absolutely. With alpha-1, of course, very high-profile disease where we have a really significant leadership position. First time ever in medical history to actually correct a broken mutation back to normal and get these patients to what looks like it should be a functional cure. There, it is all about how fast we are going. We have an incredible global site network now, and we have announced that we started dosing in July. We will be finished dosing the 50 patients in that trial by the first half of next year.
It is moving really quickly. Then we follow them for a year, and then that is the data set that we can use to file. That is really, really exciting. Then, as you noted, there is sort of a third leg of the stool for Beam, which is our metabolic sort of profile franchise. We have a program on PKU that will be dosing in early 2027. Then BEAM-301 for glycogen storage disease 1a, we just had its first clinical proof of concept data. Here, really dramatic results showing in some of these patients, reduction of cornstarch utilization and actually freedom from cornstarch in a couple of situations, and ability to fast. It is something that these patients just cannot do without going hypoglycemic.
It is basically a functional cure in an ultra-rare population.
Correct.
Yeah.
Very, very exciting for that population, and then more broadly, kind of speaks to what should be possible in PKU and in many other disorders of the liver, where we should be able to now reliably deliver the base editor, reliably fix the mutation, and that really should be a functional cure for
Might I add, the latter two programs are in vivo as well.
That's right. Yes, of all of those, the only one is ex vivo is sickle. Our LNP and mRNA capabilities are quite significant. From alpha-1 through PKU and GSD, it's all in vivo, which means two to three hour infusion and off you go.
One and done in two to three hours.
That's right.
Let's start with sickle cell. I mean, it's important. You've got an ASH presentation and an event coming up. You reported the top line data, and all is very positive. I think without comparing all the details, should be, in fact, comparable or better than the leading program from CASGEVY, Vertex. Investors look at this and they go, "I don't know, John. Vertex sales are X. They're not what the levels that they are, which people had a blockbuster indication." Should be fair because I cover Vertex. They have a couple different products, and of those couple of different products, they guided to $500 million for the year. That's a couple of different products. I think you can determine that CASGEVY is a fraction of that, or certainly not at the billions they thought. The product's actually been on the market for two years now.
Why should people think about your product, which is fairly similar to the CASGEVY product, to be better or get better utilization of commercial sales? Are there issues that Vertex has had that you think you can overcome?
Yes. I will make two arguments for you. One on the product and the differentiation we are going to bring, but then second, let us go back to the category, which I think is actually now worth looking at and turning on, as we predicted. The product, we do think it is a highly differentiated potential program. The data has been really striking all the way from, of course, the hematology outcomes where we are getting higher levels of hemoglobin F, which is the protective form, lower levels of sickle hemoglobin than has been reported by others because of the 60/40 ratio, which is similar to patients who are not diseased. They just carry this mutation. That is important for correcting blood outcomes. Second, because our edit is so gentle with the base editing, we believe, these patients are getting out of the hospital faster.
You are seeing time to neutrophil engraftment, time to platelet engraftment significantly faster than what has been seen before. That means less exposure to toxicities when you are in the transplant phase and, of course, less hospital.
Remind me, did you report out the VOE numbers?
Then that's the other piece. We have not reported that recently. I think to date, we have just said no investigator reported VOEs.
Okay.
You'll see some of that start to get reported on some of our upcoming.
Okay. We wouldn't expect that to be zero.
No, but I think that's where it's harder to differentiate because, CASGEVY and LYFGENIA are in the 89%-90% range. But I think our goal would be to be at least competitive with that, if not.
And now why I asked about some of the differentiation, appreciating that VOE, while the regulatory endpoint is going to be basically 90%
Yep
is that your team has explained that there are challenges in terms of what Vertex has had to go through in terms of getting patients
Yeah
getting them through mobilization, getting them through manufacturing success, and then ultimately delivering the product to book the revenues.
Yes.
So that can be many, many, many months
Yes
of work before getting the revenues, even though they say they have hundreds of patients ready to go. What are those challenges, and then why do you think it would be better? It is less mobilization, and you have a 99% manufacturing, because they are not at that level.
Back to our differentiation. Hematology, I think, is going to be best in class, the time to engraft and potentially best in class. Then manufacturing and process, also potentially best in class. What we have seen just in the BEACON trial is we are running significantly faster than our competitors. CASGEVY, what has been reported, and what we have heard is it can be anywhere from 9-12 months to get through the whole process. That is consistent with the slow revenue curve that we have seen. LYFGENIA, a little faster, but still, it can be long and uncertain. For us, our median time from the start of mobilization, the first time the patient shows up to get their blood collected, to when they are dosed is four and a half months. That is significantly faster. Two-thirds of patients are getting away with just one mobilization.
Your 9-12 was sort of comparing what you are hearing in the real world.
Real, well, and what was seen in the trial.
Okay.
Yep.
You are telling me you can be four and a half months.
That is right.
Now, I understand that one or two of those months are basically less mobilization cycles.
Yes.
Okay. What are the other few months?
Yeah, so less mobilization cycles is a big deal. We have our own internal manufacturing facility.
Okay
Which is not true in the field. That allows us to schedule much more compactly. We have our own quality release, right? So you are not sending this out to a bunch of different vendors around the world, check things off. It is all done internally, and then it gets back. And then also our yield, because the base editing is very strong, so we do not need as many cells to get to the same.
Okay.
All of that adds up, and it makes a big difference. We also, I think, just have benefit, frankly, of going third here, where we have been able to build on what the field knows, and our process is highly automated, highly streamlined in a way that just has not been done yet.
Okay.
I feel confident that we have a potentially differentiated product that can add meaningfully to this category. But now let me go back to the category, because I think we have predicted this. I think what I said to you even maybe last year was there is clearly demand for these patients. The problem has been manufacturing and getting it to them.
Okay. Just yesterday, Genetix came out with a press release, and they talked about LYFGENIA. This is the other product in the category. LYFGENIA is a complicated product. It is a lentivirus. But they have been, I think, more successful in delivering to patients. They have already this year booked over $300 million in sales. They are on track to hit $500 million for the annual year this year in the U.S. with LYFGENIA.
The company's profit. Okay. They are able to do this at a cost that is reasonable within those. The category of LYFGENIA plus CASGEVY, I agree Vertex doesn't fully split out their numbers, but that category
Yeah, I feel like, yeah, Vertex probably does like $200 million.
Probably $200 million. That would have been my guess.
$200 million. You are telling me they are doing $350 million.
The category between those two products this year, okay, is on track to be over $700 million.
Okay.
That is in year two, three.
Okay.
This is ramping just the way we would have guessed.
Okay.
We've always said this is not for every patient, okay? But for the 10% of patients who are really sick, this is the right choice, and that's 10,000 people.
We agree. Even for the patients that would be amenable to this, obviously analysts have built the rest. It's not on all sickle cell patients, but the people that would need this product, that is 10,000 patients, that is multi-billions and billions of dollars.
That's right.
You believe that when this product launches, you will have met the manufacturing criteria, the speed, and that's going to be a differentiator factor because you only get to pick one.
That's right.
That would be a big difference. Plus, they've grown the market, they've gotten insurance. These other people have sort of built, paved the road for you.
That's right.
A lot of those things have been sorted out.
Given this extent of demand, we are thrilled there is other products available. This is a category that is very important to these sites and these patients, but I do think there is a lot of specific demand for what we can bring with our product.
You think you can beat the launch of Vertex?
I think, stay tuned. I think at the very least, the manufacturing process that we can deliver commercially is similar to what we have done in BEACON, and we should-
Why would it not be?
be able to do that.
The same manufacturing site. You're not doing 100 patients, but you're going to be scaling up to do a lot more.
Yeah, it scales, but I think what you just put your finger on is actually quite important, which is this is the same site.
Okay.
It's really the way we did BEACON, we enrolled and dosed 50 patients in BEACON in about a year.
Okay.
All right, we have to scale that up, but not by 10x immediately.
All right.
This should be very doable.
All right. I hear a potential better launch. Now, on a low expectation
Yeah
basis.
Yeah. No, I think this is an area that investors are It's kind of time for them to lean in and learn more about it.
All right.
Because I think it's happening, and it's happening in just the way I would have guessed. It's perfect timing because we're coming.
Those are reasonable explanations for it because people have a sort of a view about what it is, but you're saying there's-
Well, LYFGENIA, to be fair, is private, right? Bluebird was bought by Carlyle. All that is happening outside of the view of the public market.
Okay.
I think now they are starting to be more clear about their numbers, and obviously, I think that is going to be helpful to people to understand
All right.
where the category is.
The second program, obviously there's been a lot of focus around this. It's a different market. This is alpha-1 antitrypsin, AAT, a potential offer people, essentially a functional cure here. You've dosed a lot of patients, and you've shown, I'm going to throw out a number, north of 15 or so µM.
On one side, that is clear proof of concept, good safety. 15 is above a general level where people think that should be carrier-like.
Yep.
Should be generally a functional cure.
Yep.
You're enrolling a pivotal study, and you just told me you're going to complete enrollment by the first half of 2027.
Yep.
Add 12 months.
Yep.
The data could be first half 2028.
Yep.
Wall Street is like, "Okay, there is three other competitors." You have some Chinese companies that have now gone public through a reverse merger that are showing north of 20, although it is small numbers. Does 20 matter versus 15? I do not know. You tell me, how should we put into context your program with the fact that Wall Street just says there is all these other programs? I think there is six, to be honest. You can correct me on the number.
Yeah.
I am told there is six.
Yeah.
What does this mean? Are we going to split this market in six people?
Any really important drug category will draw competitors.
Okay.
Right? This is drug development. This is no different.
Big market then.
Big market.
All right.
This is a big one. We are leading, which is really exciting, but obviously, I think there will be people who come. Again, it is a big enough market, it can handle multiple players, but really important to be first here, and we are. I think just building on what you asked, what you pointed out with our profile, just minding people. This is a one-time potential functional cure where you get an infusion for two to three hours for a disease that is affecting your lung and your liver for life, and is steadily progressive, and is incredibly debilitating. With that one infusion, we reliably get patients from their disease, where they have alpha-1 levels in the four to six range, and all of their alpha-1 is bad protein called Z, it is a mutant form. We take them to the mid-teens on average, okay?
Now over 90% of that protein is what we call M, which is the normal form of the protein, and a little bit left at C. Furthermore, because we fix the gene in its normal location in the genome, it has its on-off switch still. When you get sick, your body wants to make more
Okay
to protect your lungs from damage, is how the damage happens. In fact, in our case, once we've corrected the gene, when you get sick, it goes on higher, and we've shown that as well.
Okay.
We have effectively done all of the things you would need to do to take a patient from a disease profile, which we understand really well, to look, just as you said, exactly like a carrier, someone who only carries one copy of the mutation, but the other copy is normal, and those folks do not have the disease, by definition.
Okay.
That's hence the basis for saying it's a functional cure. What will competitors come to do? Our job is to bring that to patients as quickly as possible. We're racing through this 50 patient pivotal trial now. We have an alignment with the FDA that that would be submittable for an accelerated approval in the U.S. That'll be really, really exciting. And we see tremendous demand both for our program. I think the relationships we've built in this community over the last seven years are very deep.
We have a very large clinical network around the world at this point.
Why do you say that? Is it a different population than hematologists?
Totally different, of course. Yeah, in fact, it is kind of a unique population. It also is not like a liver.
Yeah.
This lives in. There are some hepatologists who study the liver failure piece of it, and then obviously, you have the COPD respiratory role.
Why do you say seven years of experience?
Oh, because you have to meet all the key affiliates.
Okay.
We are open in their sites. We are open in 15 sites, six countries around the world. That is why the enrollment is going so well.
I think we have built a tremendous amount of experience, and that is showing now in the execution of the program.
Okay. What are these competitors?
Yeah, so the competitors. I think the real question is, what can they show relative to us? It isn't clear to me there's much there. Okay? We have to wait and see. You mentioned trying to go higher in terms of average AAT level. The one company you mentioned, YolTech, coming out of China, they had one patient in the 20s who had a very high baseline. Every other patient we now know is in the teens.
Mm-hmm. Okay.
We've heard of another program that may be dosing, and I'm hearing teens as well, right?
Okay.
There's a couple more programs that haven't reached dosing patients yet.
Okay
I don't see where that results in a different profile.
Okay.
We're already providing what I think is the functional cure patients are looking for. For me, it's really all going to be about first-in-class advantage with a product that does everything that patients need it to do. That goes back to, we have at least a two-year lead on the competition because we are pioneers in the space. We've got the right relationships. I think we'll be able to launch this very successfully and maintain a kind of franchise leadership position long term.
How do you think about this indication for patients with liver disease, alpha-1 AAT, versus not? Remind me which indication you're going for and which patients would be getting this.
Yes. Critically, you have patients who have problems with both their liver and their lung.
Yeah.
Most patients have both. A few have only liver. That's pretty rare. Then some have lung just because their liver is getting worse, but slower than the lung. So we will help both. That's the key to the mechanism, right? Because every edit I make, you're no longer creating that toxic Z protein to hurt the liver, and you're now cranking out the normal M protein to protect your lungs. So you get a two-for-one benefit here. From an indication perspective, we will go after basically the 90% or so who are some lung pathology, with or without liver. Again, the reality is all of them have some liver dysfunction.
But that's the kind of core profile that we're enrolling in this Part C, the pivotal trial.
I mean, generally speaking, the people who are going to get this type of product, appreciating that the good news is the alpha-1 antitrypsin market is actually fairly well understood. There are current plasma-derived products that are approved.
Yep.
My understanding is that these companies do north of $1 billion in product with weekly infusions from plasma-derived donors.
Yep.
Who have to give their plasma to do this.
Yes.
They're doing this weekly for the rest of their life
Yes
to try and get maybe 11 µM.
Yeah.
That's doing a billion dollars, and it's weekly for the rest of your life.
That's correct.
Sanofi just did update because they have a potential monthly.
Talk about a competitor.
They are going to file sometime in 2027.
Yep.
Do you have a view about that product? I mean, to be fair, people have options, right? Monthly versus that. The market is well understood, and there are thousands and thousands of patients doing that if you multiply it out. They would have a potential one and done, but the market is identified. There is not having to find these patients. The people who are going to get gene edited are people who are pretty sick. They have the liver disease, I would think, and the lung disease, and they are identifiable. That is why they are injecting once a week.
Well, yeah. This market, there are 100,000 patients in the U.S. at least.
Okay.
Of them, 10,000 to 15,000 are diagnosed and actively being treated. There is a big diagnosis problem, so we have to work on that to bring the rest of this market online. Of those diagnosed, there are probably 8,000, 9,000 minimum who are actively on augmentation therapy. This is a known market that we can tap into. Obviously, for the pricing that we would consider, this is a very big market opportunity and a really important unmet medical need.
Think about that number. Approximately 10,000 out of the 100,000 are getting weekly infusions.
Yes.
At 10,000.
In the U.S.
In the U.S.
Yep.
If you take 1,000, so 10% penetration, on a potential $1 million drug, someone needs to fact check my math, but I think that's $10 billion TAM. So that's a pretty big market, $10 billion.
Yes, and I'd say those
10%
are conservative assumptions as well.
Okay. Yeah. Even though it's a one and done, there's $10 billion of potent, more than $10 billion
Yeah
on cash flow. Okay.
Yeah. I think it is important to then realize, I think the augmentation therapy market is, I am glad it is there for the patients, but it is not doing everything that we want it to do.
Right.
Right? First, it is incredibly life-debilitating and inconvenient. It is weekly. It is a very high infusion. That is where a three-weekly, four weekly dose would be an improvement.
But remember, with augmentation, you are doing nothing about that Z protein.
So your liver is still failing.
Totally.
And by the way, the Z that is circulating, probably not helping.
You are still making.
hurting your lung.
the bad protein.
Still making bad protein.
Still getting it in your liver.
That is right.
You are just trying to infuse corrected ones.
That's right. Furthermore, that on-off switch I mentioned is missing, right? The infused amount of protein, you have to worry about what that trough level is. When you get sick, it's not going to change.
You have as much as you put in. Whereas with us, you're going to go up. So actually, the numbers are all going to be very different. Our numbers are really a floor.
Okay.
When you get, like, we're in the mid-teens. When you get sick, you'll be in the mid-20s.
Okay.
Okay? With augmentation, you put in 11, it's just 11.
Yeah. They are not going to make any of the corrections.
That is right.
You believe that the gene edit programs, including from YolTech, are not meaningfully differentiated. You talked about teens. You are at 15.
Yep.
They are at teens. You are at least a year or more ahead, at least.
I would say at least.
Okay.
Probably more like two.
Folks like Prime, I don't even think they're in the clinic yet. Is that right?
Correct. I think they have filed.
Filed.
They're fairly-
But they're fairly behind. You're in a pivotal study.
That's right.
They have no data.
That is right.
What about things like Wave and some of those types of things?
Yeah, then you have the RNA. I think the augmentation just in general, I think, is not doing the full solution we need. With RNA editing, it is interesting. There, you are going to be creating M, you are going to be lowering Z. It will be inducible. We know that as well. The trick there is, of course, it is still a chronic therapy.
Okay.
You are on it for life.
How often do you dose?
We do not know yet. Right now in the trial, they have been doing it every few weeks, but I think we have to see what their final decision is on that. But it is going to be frequent. They are also reaching into the teens in terms of micromolar 18. The difference has been the amount of mRNA is lower.
Okay
So far, than what we are achieving. You still have
Can you clarify that? Because we get to teens, it is µM, but is not µM still functional?
The µM would be functional that they are creating. But let us say if they were at 13, 14, but only 60% of it is µM.
I see.
That would be like eight, and then the rest is still Z, right?
Okay.
Whereas we have a 14, and you are at 90% M, that means
Okay
13 of it is M and only one is
Okay.
That is the difference in the composition of what we are producing.
You are saying the headline number is overstated when they are in the teens because only 60% of that is actually the functional.
Right. What I would say is, I think the headline number is one aspect, but you have to care about the composition, and particularly how much M you're creating, how much Z you're reducing, I think is important.
Right.
All that said, I think, again, there's room in this market for RNA editing. I think it's going to be a helpful category. You had asked the question of who gets treated with gene editing, and the answer is, I actually think everybody. So, of course, you're going to go to the sick patients who need full protection. They're worried about both their lung and their liver. They're going to want the dual aspect of what Beam provides. At the same time, at the opposite end of the spectrum, you want to prevent progression.
Right? You want to go as early as you possibly can, where patients still have their lung function, before they lose it.
You can't reverse that.
You can't reverse that. You can probably reverse liver damage, is our belief, but yeah, lung damage, once it's gone, it's gone. You're going to want to actually go to the earlier patients and give them a one-time stabilization so they never get worse.
Yeah.
Right? We're seeing interest across the full spectrum of the patient population.
Okay. This product would come out in 2028?
I would say-
You file by the end of 2027.
I think if we get top-line data first half 2027.
Finish enrollment first half 2027.
Sorry, then what?
Data's first half 2028, file later, market in 2029. You are first to market.
That seems reasonable, yes.
This would be gene editing pricing.
Yep.
The idea here is that these patients are well-identified. The idea it's in vivo, not ex vivo, like sickle cell, which has some challenges. It can take months and months and months. It's a pretty debilitating, risky procedure to get that, although it's a transformative procedure.
Yep.
This would be in vivo, infusion. There is no mobilization, there is none of this, and you could stop taking your weekly infusions for the rest of your life.
Correct.
All right. Last program in the last couple minutes. I do want to talk about it briefly because you hosted a whole webcast about it. I listened to your webcast. GSD1a is interesting, but it is a very small group of patients. Then I start hearing about cornstarch, and I am like, "I do not know what is going on here." So, reduction of cornstarch. This is a disease that we are. Can you tell us about GSD1a?
Absolutely.
The idea that we could get rid of cornstarch and therefore cure these patients. Obviously, this could be a functional cure. So tell us a little bit about it.
Let me tell you the story of this disease, because I actually get
I do think about it, because when you go to the board and you're thinking about these, we know that gene editing works.
Yeah.
You said it too, right? We know it works. If you're picking the indications, you want to pick indications where it's a very straightforward mutation.
Yep.
They transform it and function. It's bad if you don't have this disease, it's bad.
Yep.
People got to get on this drug.
Yes. Let me tell you the GSD1a story, but I think, as I tell you, remember, this is just really emblematic of effectively any liver genetic disease.
Okay.
Right?
There are a lot of liver genetic diseases.
There are. But once we have shown we can do it once here, we can do it anywhere. That is the whole point. And this gets a little bit to the FDA's regulation changes, which are going to allow us to accelerate how we bring base editing to many, many patients across many diseases.
Okay.
But so the GSD1a story, this is patients who are missing one enzyme, which is required to keep their blood sugar high when they are not eating, when they are fasting. So we all go to sleep at night. We do not die of hypoglycemia because our livers create enough glucose to keep us alive. These patients cannot do that. So they are basically constantly crashing and going hypoglycemic. It takes about two and a half hours for them to drop below the critical threshold. And if they do not eat something, they can go into a coma and die. Okay? So the cornstarch is this sort of slow digested source of sugar that keeps them alive, right? So they have to take that every three hours, including overnight.
Okay? Now you have to set your alarm clock every three hours and wake up, because if you miss the alarm, you could potentially die. That means your parents also set their alarms every time to make sure you didn't sleep through your alarm.
Right. This is just primarily kids and all that?
It's for life, but from birth, you have this issue.
Okay.
I had a mother tell me, she's like, "I haven't slept through the night in 14 years.
It is a terrifying situation. Bottom line is, we want to cure these patients. All we need to do is open that pathway back up, right? Fix the one enzyme. Ultragenyx has an approved product here.
Right? So it is accelerated approval, because they showed some amount of reduction in the cornstarch, what was needed. This is an AAV gene therapy.
That was about a 44% reduction in cornstarch utilization.
Okay.
We have many patients in our first six that we showed across two dose cohorts who are in the 70% range reduction, up to 100% reduction. We have two patients who are completely off cornstarch.
70%-100%?
For many patients, not all. A couple of those patients who are fully off cornstarch, we also went to this, what is called a fasting challenge, this data I have not even seen from Ultragenyx, where you show that at baseline, patients take three hours to go hypoglycemic. Now, after the drug, we follow them, and these two patients were completely stable, able to maintain their blood sugar all the way to the end of the experiment.
They still were not hypoglycemic.
at 15 hours.
That is a full approvable endpoint, for sure. We think this is already a drug. We are very excited about it. Obviously, we are going to dose escalate one more.
We want to make sure all patients get maximum exposure to make sure they get the full benefit. We will dose an adolescent patient.
Yep
just to make sure we can get a PRV, this Priority Review Voucher, that can help fund a lot of what we are doing. Yes, it is an ultra-rare population. It is a few hundred patients. That is nonetheless helpful to us. It is meaningful impact. More importantly, it lays out the tracks for how we will do this again and again.
Okay.
Basically take a severe genetic disorder, treat and fix the mutation underlying the cause. That should lead us to expect dramatic effects and a fast path to an early approval. The next place that will be relevant is PKU.
Okay.
Right? Where we are doing the same exact thing. Right now, we have a program using these new FDA platform rules, where we have three different editors that are now going to be a part of that program. Those three editors, we think, can address up to 50% of PKU, where again, we are just going to be fixing the patient's problem.
What is the platform approval framework?
Yeah, it basically allows us to have these multi-editor products.
Yeah.
Where in a single IND, we will have multiple different guide RNAs, multiple different mRNAs, but all be part of the same clinical trial, one package, one BLA.
Okay.
Even better than that, the recent guidance from the FDA says, if you want to bring on more editors, let's say we have three in there for now, A, B, and C. If you want to bring on D through M
Yeah
you do not even need to do clinical trials for that. All you need to do is show me in vitro data that tells me this should be roughly as potent and as safe as the other ones, so long as it is kind of covered by the validation experiment you did in the clinic. That is all you need to do. Then we will go add those into the product as well.
Got it.
In fact, we think, we have estimated that with eight to 10 editors, we can get to about 80% of PKU, and we can keep going.
Right. Because for different mutations.
Different mutations.
Now, there's different mutations within the same disease.
That's right. So it really is personalized medicine.
Different mutations, your gene edit would fix that one mutation.
That is right.
But in some cases, there could be four different mutations for the population.
That is right.
Okay.
That's right.
Fantastic. That provides some context around that. Thank you very much, John. We look forward to the data at ASH and continued enrollment and progress across AATD, and thank you very much.
Thank you very much. It's an exciting time.
All right. Thank you.